End-Stage Lung Disease

Various acute and chronic lung disorders may ultimately lead to End-Stage Lung Disease (ELD). Once all options for mechanical ventilation have been exhausted, only two treatment options remain for these patients on the brink of death: extra-corporeal membrane oxygenation (ECMO) or lung transplantation. Today, however, ECMO therapy remains restricted to short-term application, primarily as a bridge to transplantation and as a bridge to recovery in acute pulmonary infections (e.g. H1N1). In chronic lung injury, transplantation remains the only available therapy with the potential of true long-term survival. This treatment option, however, may only be used in a limited number of patients, excluding those with lung tumors, and long-term survival can be severely compromised by chronic rejection. Regenerative therapies that promote endogenous lung repair, cell transplantation, or tissue engineering are currently not available. The research program therefore aims to refine transplantation procedures and further develop preoperative preparation and postoperative care in lung transplantation to minimize acute and chronic rejection. It also aims to optimize ECMO therapy towards fully implantable lung devices and set the stage for regeneration of diseased lung tissue.

Scientific Coordinators of the Disease Area

Prof. Dr. Axel Haverich (BREATH)
Prof. Dr. Veronika Grau (UGMLC)

Administrative Coordinator of the Disease Area

Dr. Annegret Zurawski (BREATH)

Participating DZL Partner Sites


News about End-Stage Lung Disease

12. April 2021

DZL Funds Four More Clinical Trials – Significant Contribution to Translational Research

Every year, DZL allocates part of its budget to innovative clinical trials that are based on initiatives by DZL scientists (Investigator Initiated Trials). Four more trials, which will be described more specifically hereinafter, will be funded as of 2021.
Read More
28. May 2020

How The Coronavirus Damages The Lungs

An international team led by DZL researcher Dr. Danny Jonigk has been able to prove changes in the lung tissue caused by SARS-CoV-2. The findings of the study show a funda-mental difference to lung damage caused by influenza viruses.
Read More
26. June 2014

DZL PI Prof. Dr. Axel Haverich Receives Fritz Behrens Prize

DZL PI Prof. Dr. Axel Haverich was honored with the renowned Fritz Behrens Prize for his life’s work on June 17th in Hannover.

Read More
All End-Stage Lung Disease news